Business Context and Reporting Period
This Form 8-K filing by Intelligent Bio Solutions Inc. (INBS) covers the reporting period ending January 7, 2026. The filing addresses a specific regulatory event regarding the company's listing status on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on stock price compliance rather than financial performance metrics.
Material Changes
The primary material change reported is the resolution of a Nasdaq listing deficiency:
- Prior Status: On December 16, 2025, the company received a deficiency notice for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days.
- Current Status: On January 7, 2026, Nasdaq notified the company that it regained compliance. The stock closed at $1.00 or greater for 14 consecutive business days (December 16, 2025, to January 6, 2026).
- Outcome: The listing matter is now closed, and the company is in compliance with Nasdaq Listing Rule 5550(a)(2).
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operations, or discussion of new risks or contingencies. The document serves solely to confirm the closure of the bid price deficiency matter.
Investor Verification Checklist
- Verify the current trading price of INBS to ensure it remains above the $1.00 threshold to avoid future deficiency notices.
- Review the December 16, 2025, Form 8-K to understand the initial context of the bid price deficiency.
- Confirm the company's status as an emerging growth company (indicated as "Yes" in the filing) and its implications for financial reporting.